5 Best Biotech Stocks to Buy According to Alan Frazier

2. Krystal Biotech, Inc. (NASDAQ: KRYS)

Frazier’s Stake Value: $68,951,000
Percentage of Alan Frazier’s 13F Portfolio: 5.53%
Number of Hedge Fund Holders: 8 

Krystal Biotech, Inc. (NASDAQ: KRYS) is an American biotech company engaged in the field of redosable gene therapy to treat serious rare diseases. The company was incorporated in 2015 and is ranked second on the list of 10 best biotech stocks to buy according to Alan Frazier. Krystal currently has a $1.53 billion market capitalization. It delivered a 48.72% return in the past 12 months.

On March 30, Krystal Biotech, Inc. (NASDAQ: KRYS) declared that it completed enlistment in the GEM-3 study of B-VEC for dystrophic epidermolysis bullosa. The trial registered 31 patients ranging in ages from 1 to 44 years old. On February 9, Jones Trading initiated coverage on Krystal Biotech with a “Buy” rating and a price target of $97.

Frazier Healthcare Partners owns 895,000 shares of Krystal Biotech, worth $68.95 million, making it the second-largest company stakeholder. Redmile Group is a leading shareholder in Krystal Biotech, Inc. (NASDAQ: KRYS), with 2.06 million shares worth $158.71 million, representing 2.23% of its portfolio.